Segment Reporting

12 Months Ended

Dec. 31, 2024

Segment Reporting

Segment Reporting

15. Segment Reporting

The Company operates and manages its business as one reportable operating segment, which is the business of developing a pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology. The determination of a single business segment is consistent with the consolidated financial information regularly provided to the Company’s chief operating decision maker (“CODM”). The Company’s CODM is its Chief Executive Officer, who reviews financial information on an aggregate basis for purposes of assessing performance, making operating decisions, allocating resources and evaluating financial performance. The long-lived assets of $14.0 million, which represents 99.3% of the Company’s total long-lived assets, are maintained in the United States.

The following table includes certain segment information for the years ended December 31, 2024 and 2023.

	Year Ended December 31,
	2024		2023
Grant revenue	$	5,174	$	4,529
Operating expenses
Research and development expenses:
AP-PA02: Non-Cystic Fibrosis Bronchiectasis		6,840		4,922
AP-PA02: Cystic Fibrosis		236		1,692
AP-SA02: Bacteremia		4,177		4,789
AP-SA02Prosthetic Joint Infection		35		202
Expenses not allocated by projects		2,408		3,042
Total external research and development expenses		13,696		14,647
Research and development personnel expenses		10,764		9,408
Other research and development expenses		9,966		9,715
Total research and development expenses		34,426		33,770
General and administrative expenses:
General and administrative personnel expenses		4,935		2,480
Other general and administrative expenses		8,249		9,169
Total general and administrative expenses		13,184		11,649
Total operating expenses		47,610		45,419
Operating loss		(42,436)		(40,890)
Other income (expense), net		23,520		(28,155)
Net loss	$	(18,916)	$	(69,045)